58695-41-3

Usage

InChI:InChI=1/C8H15NO2/c10-8(11)6-9-7-4-2-1-3-5-7/h7,9H,1-6H2,(H,10,11)

Upstream product

• 1074-58-4 N-(cyanomethyl)cyclohexylamine 
• 23605-23-4 2-Chloro-N-cyclohexylacetamide 
• 37883-45-7 ethyl N-cyclohexylglycinate 
• 108-91-8 cyclohexylamine 
• 598-21-0 2-Bromoacetyl bromide 
• 103-01-5 N-Phenylglycine 
• 121-44-8 triethylamine 
• 5437-45-6 Benzyl bromoacetate 
• 105-36-2 ethyl bromoacetate 
• 5292-43-3 bromoacetic acid tert-butyl ester 
• 623-50-7 ethyl 2-hydroxyacetate 
• 4998-76-9 cyclohexylamine hydrochloride 

Downstream Products

• 117039-56-2 N-cyclohexyl-N-nitroso-glycine 
• 116-52-9 dichloralurea 
• 635288-69-6 4-bromo-N-[(1S)-1-cyclohexyl-2-hydroxyethyl] benzenesulfonamide 
• 40447-13-0 N-cyclohexylglycine methyl ester 
• 208255-68-9 N-[N-(isovaleryl)-2-amino-2-cyclohexylacetyl]-L-alanine ethyl ester 
• 38650-70-3 4-acetyl-3-cyclohexyl-sydnone 
• 20600-69-5 3-cyclohexyl-sydnone 

Relevant academic research and scientific papers

2-Mercapto-Quinazolinones as Inhibitors of Type II NADH Dehydrogenase and Mycobacterium tuberculosis: Structure-Activity Relationships, Mechanism of Action and Absorption, Distribution, Metabolism, and Excretion Characterization

Mycobacterium tuberculosis (MTb) possesses two nonproton pumping type II NADH dehydrogenase (NDH-2) enzymes which are predicted to be jointly essential for respiratory metabolism. Furthermore, the structure of a closely related bacterial NDH-2 has been reported recently, allowing for the structure-based design of small-molecule inhibitors. Herein, we disclose MTb whole-cell structure-activity relationships (SARs) for a series of 2-mercapto-quinazolinones which target the ndh encoded NDH-2 with nanomolar potencies. The compounds were inactivated by glutathione-dependent adduct formation as well as quinazolinone oxidation in microsomes. Pharmacokinetic studies demonstrated modest bioavailability and compound exposures. Resistance to the compounds in MTb was conferred by promoter mutations in the alternative nonessential NDH-2 encoded by ndhA in MTb. Bioenergetic analyses revealed a decrease in oxygen consumption rates in response to inhibitor in cells in which membrane potential was uncoupled from ATP production, while inverted membrane vesicles showed mercapto-quinazolinone-dependent inhibition of ATP production when NADH was the electron donor to the respiratory chain. Enzyme kinetic studies further demonstrated noncompetitive inhibition, suggesting binding of this scaffold to an allosteric site. In summary, while the initial MTb SAR showed limited improvement in potency, these results, combined with structural information on the bacterial protein, will aid in the future discovery of new and improved NDH-2 inhibitors.

Soluble Polymer-Supported Synthesis of α-Amino Acid Derivatives

A practical and efficient synthesis of N-substituted α-amino acid derivatives on soluble polymer support is described.

ANTITHROMBOTIC AGENTS

This invention relates to thrombin inhibiting compounds having the Formula IX--Y--NH--(CH 2) r--G I where X, Y, r and G have the values defined in the description, as well as pharmaceutical formulations containing those compounds and methods of their use as thrombin inhibitors, coagulation inhibitors, and thromboembolic disorder agents.

Mesoionic compounds. 10. Preferred conformation of a 3-alkyl and 3-aryl-substituent in 4-unsubstituted and 4-acylated monocyclic munchnones and sydnones

A new 4-unsubstituted monocyclic oxazolium-5-olate (7c) was generated and NMR-characterized. Several 3-alkyl- and 3-aryl-4-acylated monocyclic munchnone and sydnone derivatives were also prepared. From NMR experimental data and theoretical calculations di

Peptide compounds, their preparation and uses

A compound of the formula: STR1 in which R4 is acyl, R5 is lower alkyl, R6 is optionally substituted ar(lower)alkyl or optionally substituted heterocyclic-(lower)alkyl, R7 is lower alkyl or lower alkylthio(lower)alkyl, R8 is carboxy or protected carboxy, A is lower alkylene, Z is a group of the formula: STR2 wherein R1 is hydrogen, lower alkyl, common amino-protective group or optionally substituted ar(lower)alkyl, R2 is hydrogen, lower alkyl, optionally substituted ar(lower)alkyl, optionally substituted heterocyclic-(lower)alkyl, optionally substituted cyclo(lower)alkyl(lower)alkyl, common amino-protective group, amino(or protected amino)(lower)alkyl, optionally substituted heterocyclic-carbonyl or cyclo(lower)alkyl, and R3 is optionally substituted heterocyclic(lower)alkyl, and m is an integer of 0 to 2, or pharmaceutically acceptable salts thereof, useful as endothelin antagonist.

ANTITHROMBOTIC AGENTS

This invention relates to thrombin inhibiting compounds having the FormulaIX--Y--NH--(CH 2) r--G I where X, Y, r and G have the values defined in the description, as well as pharmaceutical formulations containing those compounds and methods of their use as thrombin inhibitors, coagulation inhibitors, and thromboembolic disorder agents.

ANTITHROMBOTIC AGENTS

This invention relates to thrombin inhibiting compounds having the FormulaIX--Y--NH--(CH 2) r--G I where X, Y, r and G have the values defined in the description, as well as pharmaceutical formulations containing those compounds and methods of their use as thrombin inhibitors, coagulation inhibitors, and thromboembolic disorder agents.

ANTITHROMBOTIC AGENTS

This invention relates to thrombin inhibiting compounds having the FormulaIX--Y--NH--(CH 2) r--G I where X, Y, r and G have the values defined in the description, as well as pharmaceutical formulations containing those compounds and methods of their use as thrombin inhibitors, coagulation inhibitors, and thromboembolic disorder agents.

ANTITHROMBOTIC AGENTS

This invention relates to thrombin inhibiting compounds having the FormulaIX--Y--NH--(CH 2) r--G I where X, Y, r and G have the values defined in the description, as well as pharmaceutical formulations containing those compounds and methods of their use as thrombin inhibitors, coagulation inhibitors, and thromboembolic disorder agents.

PHOSPHONYL HYDROXYACYL AMINO ACID DERIVATIVES AS ANTIHYPERTENSIVES

Phosphonyl hydroxyacyl amino acids of the formula STR1 wherein X is a substituted or unsubstituted imino or amino acid or ester. These compounds possess angiotensin converting enzyme activity and are thus useful as hypotensive agents.